The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors

Semiconductors

July 06, 2022

Buy ($175)

Companies covered: Marvell Technology Group Ltd. (NASDAQ:MRVL), Analog Devices, Inc. (NASDAQ:ADI), Silicon Laboratories, Inc. (NASDAQ:SLAB), MaxLinear, Inc (NYSE:MXL), Credo Technology Group Holding Ltd. (NASDAQ:CRDO), inTest Corporation (NYSEAMERICAN:INTT), Navitas Semiconductor Corp. (NASDAQ:NVTS), Peraso Inc. (NASDAQ:PRSO), POET Technologies Inc. (NASDAQ:POET)

Cars, Broadband, Industrial Uses Intensify Semiconductor Demand
Tore Svanberg
Interview with the President and CEO: inTEST Corporation (NYSEAMERICAN:INTT)
Richard N. Grant
Interview with the CEO: Navitas Semiconductor Corp. (NASDAQ:NVTS)
Gene Sheridan
Interview with the CEO: Peraso Inc. (NASDAQ:PRSO)
Ronald Glibbery
Interview with the Chairman and CEO: POET Technologies Inc. (NASDAQ:POET)
Suresh Venkatesan
Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the President and CEO: PDS Biotechnology Corporation (NASDAQ:PDSB)
Interview with the Founder and Executive Chairman: Organovo Holdings Inc. (NASDAQ:ONVO)
Interview with the Co-Founder and CEO: Equillium Inc. (NASDAQ:EQ)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Electric Cars and AI Fuel Long-Term Electricity Demand
Separating the Real Winners and Losers in the AI Boom
Generating Dividend Yield That’s Not Correlated to Interest Rates
ANALYST INTERVIEWS
Robust M&A Activity Provides Tailwind to Biotech Sector
Seeking Out Game Changers in Re-Emerging Biotech Sector
Obesity Drugmakers Still a ‘Buy’ Despite Lofty Valuations
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy